Patient Adherence and Persistence With Oral Anticancer Treatment

被引:473
作者
Ruddy, Kathryn [1 ]
Mayer, Erica [1 ]
Partridge, Ann [1 ]
机构
[1] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Breast Oncol, Boston, MA 02115 USA
关键词
DRUG-THERAPY; TAMOXIFEN THERAPY; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; MEDICATION COMPLIANCE; POSTMENOPAUSAL WOMEN; RANDOMIZED-TRIAL; OLDER WOMEN; DISCONTINUATION; NONCOMPLIANCE;
D O I
10.3322/caac.20004
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Given the recent significant increase in the use of oral therapies in cancer-management, an understanding of patients' adherence to and persistence with oral therapy is crucial. Nonadherence and early cessation may be substantial barriers to the delivery of valuable therapies, and may impair health. Potential obstacles to adherence and persistence include personal characteristics, treatment features, and system factors. Techniques for measuring adherence and persistence include self report, pill counts, microelectronic monitoring systems (MEMS), prescription database analysis, and the assessment of serum or urine drug levels. This review article describes available data regarding adherence and persistence among patients with cancer, as well as studies of interventions to improve adherence. All reports of studies of adherence with oral cancer therapy that the authors could find on PubMed or in the reference sections of these PubMed-located articles were included. Adherence and persistence rates ranged from 16% to 100% with different therapies and different methods of Measurement. Studies that included educational, behavioral, and multidimensional interventions to improve adherence were also described. CA Cancer J Clin 2009;59:56-66. (C) 2009.American Cancer-Society.
引用
收藏
页码:56 / 66
页数:11
相关论文
共 82 条
[1]
ALLEN S, 2007, BOSTON GLOBE 0204
[2]
[Anonymous], COMMUNITY ONCOL
[3]
Intentional and non-intentional non-adherence to medication amongst breast cancer patients [J].
Atkins, Louise ;
Fallowfield, Lesley .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (14) :2271-2276
[4]
Persistence of use of lipid-lowering medications - A cross-national study [J].
Avorn, J ;
Monette, J ;
Lacour, A ;
Bohn, RL ;
Monane, M ;
Mogun, H ;
LeLorier, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1458-1462
[5]
Early discontinuation of tamoxifen - A lesson for oncologists [J].
Barron, Thomas I. ;
Connolly, Roisin M. ;
Bennett, Kathleen ;
Feely, John ;
Kennedy, M. John .
CANCER, 2007, 109 (05) :832-839
[6]
HEALTH BELIEF MODEL AND PREDICTION OF DIETARY COMPLIANCE - FIELD EXPERIMENT [J].
BECKER, MH ;
MAIMAN, LA ;
KIRSCHT, JP ;
HAEFNER, DP ;
DRACHMAN, RH .
JOURNAL OF HEALTH AND SOCIAL BEHAVIOR, 1977, 18 (04) :348-366
[7]
Bedell Cindi Holt, 2003, Clin J Oncol Nurs, V7, P5, DOI 10.1188/03.CJON.S6.5-9
[8]
Beney J., 2000, COCHRANE DB SYST REV, pCD000336, DOI [10.1002/14651858.cd000336, DOI 10.1002/14651858.CD000336]
[9]
BLACKWELL B, 1972, LANCET, V1, P1279
[10]
DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].
BONADONNA, G ;
VALAGUSSA, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15